Share on StockTwits

Derma Sciences (NASDAQ:DSCI) reached a new 52-week low on Friday , AnalystRatingsNetwork reports. The company traded as low as $8.41 and last traded at $8.50, with a volume of 45,789 shares changing hands. The stock had previously closed at $8.56.

Several analysts have recently commented on the stock. Analysts at Oppenheimer cut their price target on shares of Derma Sciences from $19.00 to $18.00 in a research note on Thursday, August 14th. They now have an “outperform” rating on the stock. Separately, analysts at Canaccord Genuity cut their price target on shares of Derma Sciences from $19.00 to $18.00 in a research note on Friday, August 8th. Finally, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Derma Sciences in a research note on Wednesday, June 18th. They now have a $19.00 price target on the stock, up previously from $18.00.

The stock’s 50-day moving average is $9.8 and its 200-day moving average is $11.09. The company’s market cap is $214.6 million.

Derma Sciences (NASDAQ:DSCI) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.12. On average, analysts predict that Derma Sciences will post $-1.62 earnings per share for the current fiscal year.

Derma Sciences, Inc (NASDAQ:DSCI), is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care, advanced wound care and traditional wound care products.

Receive News & Ratings for Derma Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.